United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $516.06, for a total value of $4,902,570.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $167,432,054.58. This represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
United Therapeutics Trading Up 0.5%
Shares of NASDAQ UTHR opened at $518.68 on Wednesday. The firm has a market cap of $22.02 billion, a P/E ratio of 19.15, a price-to-earnings-growth ratio of 1.73 and a beta of 0.59. The business’s 50 day moving average is $541.40 and its 200-day moving average is $533.37. United Therapeutics Corporation has a 1-year low of $291.22 and a 1-year high of $609.35.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the firm earned $6.63 earnings per share. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Analysts forecast that United Therapeutics Corporation will post 26.65 EPS for the current year.
Institutional Trading of United Therapeutics
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on UTHR shares. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research report on Thursday, May 7th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Bank of America cut their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $648.33.
Read Our Latest Stock Report on UTHR
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
- Five stocks we like better than United Therapeutics
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
